Immune-checkpoint blockade (ICB) therapy has changed the clinical outcome of many types of aggressive tumors. but there still remain many cancer patients that do not respond to these treatments. There is an unmet need to develop a feasible clinical therapeutic platform to increase the rate of response to ICB. Here we use a previously described clinically tested aptamer (AS1411) conjug... https://www.muttsandscoers.shop/product-category/steam/